Table 2.
Adjuvant therapy among patients with residual disease
| Residual disease by site | No adjuvant therapy, n (%) | Capecitabine alone or with other chemotherapy, n (%) | Other chemotherapy, n (%) | Endocrine/targeted therapy only, n (%) |
|---|---|---|---|---|
| DFCI (RD 191/267, 71.5%) | 76 (39.8) | 52 (27.2) | 56 (29.3) | 7 (3.7) |
| MDACC (RD 386/553, 69.8%) | 173 (44.8) | 127 (32.9) | 50 (13.0) | 36 (9.3) |
| OSU (n = 84/157, 53.5%) | 49 (58.3) | 23 (27.4) | 9 (10.7) | 3 (3.6) |
| Total (N = 661) | 298 (45.1) | 202 (30.6) | 115 (17.4) | 46 (7.0) |
DFCI, Dana-Farber Cancer Institute; MDACC, The University of Texas MD Anderson Cancer Center; OSU, The Ohio State University Comprehensive Cancer Center; RD, residual disease.